Hers Safety, Regulation, and Compliance Posture

Corporate Structure and Licensing

Hers operates as a brand under Hims & Hers Health, Inc., a Delaware-incorporated company traded on the NYSE since January 2021. The corporate structure matters for safety assessment because it subjects the company to SEC disclosure requirements, quarterly financial audits, and public reporting of material legal and regulatory risks. In its 2024 10-K filing, the company disclosed active monitoring by state pharmacy boards and the FTC regarding advertising claims [1].

Telehealth platforms like Hers do not hold a single federal medical license. Each prescribing provider must be individually licensed in the patient's state of residence, a requirement enforced by state medical boards under the Federation of State Medical Boards (FSMB) telehealth policy framework [2]. Hers states it credentials all providers, but independent verification is difficult because the platform does not publicly list its physician roster. Patients can verify a specific provider's license through their state medical board after receiving a prescription.

The distinction between a technology platform and a medical practice is significant. Hers itself does not practice medicine. It operates what the FSMB classifies as a "telehealth facilitator," connecting patients with independently licensed clinicians who bear individual malpractice liability [2]. This distributed model means regulatory accountability falls on individual providers rather than the corporate entity, a structure that can limit patients' recourse if care quality issues arise.

Telehealth Prescribing Standards

Federal telehealth prescribing expanded during the COVID-19 public health emergency under the Ryan Haight Act waiver, which the DEA extended through 2025 [3]. For non-controlled substances (the bulk of Hers' formulary), prescribing via asynchronous questionnaire remains legal in most states. Controlled substance prescribing requires synchronous audio-video evaluation in 38 states as of 2025, though specific requirements continue to shift.

The quality of asynchronous prescribing has drawn scrutiny. A 2021 study published in JAMA Internal Medicine examined antibiotic prescribing on direct-to-consumer telehealth platforms and found that 45.2% of visits resulted in guideline-discordant prescriptions [4]. While that study focused on antibiotics rather than the dermatologic or hormonal medications Hers prescribes, it highlights a structural concern: asynchronous encounters with minimal history-taking may produce less rigorous clinical decision-making than in-person or synchronous video visits.

For hormone replacement therapy specifically, the Endocrine Society's 2019 clinical practice guideline recommends individualized risk assessment including cardiovascular risk scoring, breast cancer history evaluation, and baseline laboratory work before initiating estrogen or progesterone therapy [5]. Whether Hers' intake questionnaire captures this level of clinical detail is not independently auditable from publicly available information. The platform states that lab work is required for certain prescriptions, but does not specify which ones.

Pharmacy and Compounding Oversight

Hers distributes medications through two channels: retail pharmacy partners dispensing FDA-approved drugs, and affiliated compounding pharmacies producing custom formulations. These channels carry fundamentally different risk profiles.

FDA-approved medications dispensed through licensed retail pharmacies (finasteride, minoxidil, tretinoin, branded estradiol patches) undergo the standard regulatory pathway: phase III clinical trials, FDA review, cGMP manufacturing, and post-market surveillance through the FDA Adverse Event Reporting System (FAERS) [6]. The safety data for these drugs is extensive and publicly accessible.

Compounded medications occupy a different regulatory tier. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce patient-specific formulations without FDA pre-approval, provided they meet certain conditions: a valid prescription, use of bulk drug substances from FDA-registered facilities, and compliance with USP standards [7]. The FDA does not verify the safety or efficacy of individual compounded preparations. A 2012 fungal meningitis outbreak linked to the New England Compounding Center killed 76 patients, prompting Congress to pass the Drug Quality and Security Act (DQSA) of 2013, which created a voluntary registration pathway (503B outsourcing facilities) with enhanced FDA oversight [7].

Whether Hers' compounding partners operate as 503A or 503B facilities directly affects patient safety. 503B outsourcing facilities submit to FDA inspection and must follow cGMP standards. 503A pharmacies face state-level oversight only, which varies dramatically in rigor. Hers has not publicly disclosed which regulatory pathway its compounding partners follow.

The Compounded Semaglutide Question

The highest-profile safety and regulatory issue facing Hers involves compounded semaglutide. Novo Nordisk's branded semaglutide (Wegovy, Ozempic) is FDA-approved, but supply shortages beginning in 2022 led compounding pharmacies to produce semaglutide using bulk drug substance [8]. Hers began offering compounded semaglutide for weight management during this shortage period.

The FDA's position has been firm. In October 2023, the agency issued warning letters to compounding pharmacies producing semaglutide, stating that semaglutide base (not the sodium salt form used in Wegovy) is not the same active ingredient and that compounded versions had not demonstrated bioequivalence [8]. The FDA also reported adverse events associated with compounded semaglutide, including dosing errors and contamination concerns.

In its clinical trials, branded semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) [9]. These efficacy and safety data apply exclusively to the branded product manufactured under cGMP conditions. Compounded semaglutide has no equivalent trial data, no published bioequivalence studies, and no FDA safety review.

Dr. Janet Woodcock, then-Principal Deputy Commissioner of the FDA, stated in a 2023 public advisory: "Patients using compounded versions of GLP-1 receptor agonists may be exposed to products that vary in purity, potency, and sterility compared to the FDA-approved versions" [8]. This risk applies to any platform dispensing compounded semaglutide, Hers included.

As of early 2026, the FDA removed semaglutide from its drug shortage list, which under 503A rules should have ended the legal basis for compounding it. Hers' continued offering of compounded GLP-1 products after shortage resolution represents a significant regulatory gray area.

Women's HRT Offerings and Clinical Evidence

Hers prescribes estradiol, progesterone, and spironolactone for menopausal symptoms and androgen-related conditions. The clinical evidence base for these medications is well established through FDA-approved pathways.

The Women's Health Initiative (WHI) remains the largest randomized trial of postmenopausal hormone therapy. The estrogen-plus-progestin arm (N=16,608) found a hazard ratio of 1.26 for invasive breast cancer and 1.29 for coronary heart disease, but a 0.63 hazard ratio for hip fracture [10]. The estrogen-alone arm (N=10,739) showed no increased breast cancer risk over 7.2 years of follow-up [10]. These data informed the current consensus, articulated by the North American Menopause Society (NAMS) in its 2022 position statement, that "for women aged younger than 60 years or who are within 10 years of menopause onset, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [11].

The NAMS position statement also specifies that "hormone therapy should be individualized based on the woman's symptoms, health history, and preferences, using the lowest effective dose for the shortest duration consistent with treatment goals" [11]. Whether Hers' questionnaire-based model achieves this individualization is the central clinical question. Asynchronous intake forms can capture symptoms and contraindications, but lack the nuance of a real-time clinical conversation about risk tolerance, family history depth, and treatment alternatives.

For spironolactone prescribed for acne and hair loss, a 2020 systematic review in the Journal of the American Academy of Dermatology (19 studies, N=1,378) found significant improvement in acne and hirsutism with doses of 50 to 200 mg daily, with hyperkalemia occurring in 3% to 5% of patients [12]. Standard practice requires baseline potassium monitoring and periodic rechecking. Hers' protocols for lab monitoring of spironolactone patients have not been independently evaluated.

Adverse Event Signals and Consumer Complaints

Hers has not been the subject of FDA enforcement actions, consent decrees, or warning letters directed at the corporate entity as of May 2026. This is a meaningful data point but not definitive proof of safety, since the FDA's enforcement capacity is limited and the agency prioritizes manufacturing facilities over telehealth platforms.

The FTC has taken a broader interest in telehealth subscription models. In 2024, the agency proposed updates to its "click-to-cancel" rule requiring that subscription services make cancellation as simple as sign-up [13]. Consumer complaints about Hers have concentrated on billing and cancellation friction rather than clinical safety, based on publicly available BBB and Trustpilot reviews. These are business practice concerns rather than patient safety signals, but they reflect on the company's overall consumer protection posture.

FAERS data for medications commonly prescribed by Hers (finasteride, minoxidil, spironolactone, sertraline) reflect adverse event profiles of the drugs themselves, not the platform's prescribing patterns [6]. No publicly available dataset isolates adverse events by prescribing platform, making it impossible to compare Hers' clinical outcomes to those of traditional prescribers.

How Hers Compares to Alternatives on Safety

The telehealth market for women's health includes Hers, Midi Health, Alloy, Evernow, and Winona, among others. Safety differentiation comes down to three factors: prescriber qualification, compounding practices, and clinical monitoring protocols.

Midi Health, for example, markets itself as menopause-specialist care and uses synchronous video visits with board-certified providers who have menopause-specific training [14]. This model aligns more closely with NAMS recommendations for individualized hormone therapy assessment. Evernow also uses synchronous video consultations and requires baseline labs before prescribing HRT.

Hers' asynchronous model offers convenience and lower cost (subscriptions starting at $25 to $85 per month depending on treatment category) but trades away some of the clinical depth that synchronous evaluation provides. For straightforward dermatologic prescriptions like tretinoin, this tradeoff may be clinically acceptable. For hormone therapy with cardiovascular and oncologic risk considerations, the tradeoff deserves more scrutiny.

A 2023 cross-sectional analysis published in Annals of Internal Medicine examined 40 direct-to-consumer telehealth platforms and found that only 55% required any form of laboratory testing before prescribing hormonal medications [15]. Hers fell in the majority that required labs for some but not all hormonal prescriptions. The study's authors concluded that "standardized clinical protocols and mandatory lab requirements could improve patient safety across the direct-to-consumer telehealth sector" [15].

What to Verify Before Starting Treatment Through Hers

Patients considering Hers should confirm four things independently. First, verify the prescribing provider's active license through your state medical board's online lookup tool. Second, ask whether your specific medication is FDA-approved or compounded, and if compounded, whether the pharmacy is a 503B outsourcing facility subject to FDA inspection. Third, confirm what laboratory monitoring the platform requires before and during treatment. The Endocrine Society recommends baseline lipid panel, hepatic function, and mammography within the past year before initiating HRT in women over 40 [5]. Fourth, understand cancellation terms before providing payment information, given the volume of consumer complaints about subscription billing.

For compounded semaglutide specifically, patients should be aware that the FDA considers these products unapproved drugs when no shortage exists, and that no bioequivalence data support interchangeability with Wegovy or Ozempic [8]. Branded semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent data, with the STEP trials reporting a 0.3% incidence of cholelithiasis and 1.4% incidence of acute pancreatitis-related adverse events at the 2.4 mg dose [9].